Gold prices steady with focus on Ukraine-Russia, Jackson Hole
On Tuesday, Stifel analysts maintained a Buy rating on Alcon Inc. (NYSE: NYSE:ALC) shares with a price target of $100.00. The company, with a market capitalization of $44 billion and annual revenue of $9.9 billion, is a prominent player in the Healthcare Equipment & Supplies industry. According to InvestingPro data, Alcon maintains a GREAT financial health score, supported by strong liquidity and moderate debt levels. They focused on the upcoming Prescription Drug User Fee Act (PDUFA) date of May 30 for Alcon’s AR-15512 (acoltremon), an innovative eyedrop treatment for dry eye disease (DED). The analysts highlighted acoltremon’s unique mechanism, which stimulates natural tear production and its rapid onset, as key differentiators in the market.
While the analysts are optimistic about the drug’s approval, given its positive phase 3 data, they also noted several concerns that could moderate the product’s launch. These include the prevalence of a burning or stinging sensation, although transient, and mixed phase 3 symptomatic data that could result in a limited label. Additionally, they pointed out the increasingly competitive landscape with products like Miebo, Vevye, and Xiidra, as well as Alcon’s need to expand its DED salesforce. The company’s strong gross profit margin of 55.6% provides financial flexibility for such expansion initiatives. For deeper insights into Alcon’s competitive position and growth potential, InvestingPro subscribers can access the comprehensive Pro Research Report, which includes detailed analysis of the company’s market position and growth drivers.
Despite these challenges, Stifel analysts expect the acoltremon launch to contribute moderately to Alcon’s sales, forecasting revenues of approximately $70 million in 2026 and $130 million in 2027. This is anticipated to contribute to an incremental sales growth of around 60 basis points in 2026 and 50 basis points in 2027 for Alcon. The analysts believe this will support the bullish thesis on Alcon’s product cycle-driven growth acceleration, although perhaps not as strongly as some might hope. Currently trading at a P/E ratio of 39.5x, InvestingPro analysis suggests the stock is slightly overvalued relative to its Fair Value, with analysts maintaining a consensus Buy rating and a high price target of $120.
In other recent news, Alcon Inc. has been the focus of several analyst assessments following its recent Capital Markets Day, which revealed strategic plans for growth and innovation. Deutsche Bank (ETR:DBKGn) downgraded Alcon from Buy to Hold, citing concerns about a slowdown in end markets and potential challenges in meeting full-year guidance. However, Deutsche Bank also raised its price target to CHF96.00, reflecting optimism about Alcon’s future product launches. Meanwhile, Bernstein adjusted its price target for Alcon to $109.00, maintaining an Outperform rating despite a weaker second-quarter outlook due to increased R&D and SG&A expenses. Bernstein also raised its Swiss price target to CHF99.00, encouraged by Alcon’s robust product pipeline for 2025 and beyond. KeyBanc expressed confidence in Alcon’s growth potential, increasing its price target to $112 and highlighting the company’s strategic focus on innovation and double-digit earnings growth. These developments underscore a mixed but generally optimistic sentiment among analysts regarding Alcon’s market strategy and future performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.